IL-DURAVANT
22.2.2021 13:02:06 CET | Business Wire | Press release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced the acquisition of Votech GS B.V. (“Votech”), a leading manufacturer of bag filling machines, palletizer machines, stretch hood machines and pallet transport systems headquartered in Reusel, The Netherlands. Votech will join forces with Fischbein International, a Duravant Operating Company, to serve their global customer base.
The combination of Votech’s expertise in bag management and palletizing and Fischbein’s portfolio of bag sealing and sewing equipment creates a complementary fit between the two companies.
“There is a very complementary relationship between our two organizations,” said Olivier Hancotte, VP and General Manager of Fischbein. “We’re thrilled to work closely with the Votech team to create a broader product offering for both companies’ customers. Fischbein and Votech equipment will both be available through the Fischbein global sales team.”
This partnership brings together two global engineered equipment leaders and extends Duravant’s ability to serve customers and partners in over 190 countries worldwide across multiple sectors including agriculture, industrials, fruit and vegetables, ingredients, pet food and more.
“We’re excited to be a part of the Duravant group of world-class brands and automation solutions,” said Rolf Michiels, Director of Project Sales. “Aligning with the Fischbein team to better serve our customers through a united and collaborative strategy is an exciting prospect for us. Duravant’s lifecycle management via the company’s SupportPro services also gives our customers broader access to value-added solutions that will help their operations achieve their productivity and efficiency goals.”
The Votech brand of packaging machinery has been a competitive force in filling and bag management for over a decade. Votech’s deep engineering and development capabilities allow for the custom design of complete automated solutions from the filling of a bag, to the internal pallet transport to the warehouse. Recognized for superior engineering, package control and local field service support, Votech has proven success delivering packaging solutions for free-flowing and powders applications.
“Our partnership with Duravant opens the path for Votech’s geographic expansion and growth in Europe, the Middle-East, Africa and North America,” adds Pierre Dierckx, Director of Operations. “We’re thrilled to also collaborate with nVenia, Duravant’s US-based operating company serving customers across a wide array of industrial end markets and consumer packaged goods.” The Votech solution set for powders applications is highly complementary with the nVenia product range across primary, secondary and end-of-line packaging.
About Duravant
Headquartered in Downers Grove, IL, Duravant is a global engineered equipment company with manufacturing, sales and service facilities throughout North America, Europe and Asia. Through their portfolio of operating companies, Duravant delivers trusted end-to-end process solutions for customers and partners through engineering and integration expertise, project management and operational excellence. With worldwide sales distribution and service networks, they provide immediate and lifetime aftermarket support to all the markets they serve in the food processing, packaging and material handling sectors. Duravant’s market-leading brands are synonymous with innovation, durability and reliability. For more information, visit www.duravant.com .
About Votech
Headquartered in Reusel, The Netherlands, Votech specializes in developing bag filling and palletizer machines, stretch hood machines and transport systems. The Votech brand has been recognized for providing complete packaging lines from the filling of a bag, through to the internal pallet transport to the warehouse. The entire Votech equipment portfolio is available through Fischbein, a Duravant Company. For more information, visit www.votechbv.co.uk .
About Fischbein
Fischbein designs and manufactures bag packaging equipment and complete systems. For over 100 years, Fischbein has been the leader in sewing and sealing systems by delivering highly engineered, robust and dependable solutions. Serving customers worldwide in agriculture, animal feed, seed, pet food, chemical, mineral, milling, food, building material, medical and pharmaceutical industries, Fischbein has a full range of sealing, filling, weighing, handling, and palletizing equipment that is sold and serviced in more than 190 countries. Fischbein is a Duravant Company. For more information, visit www.fischbein.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005061/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
